Cenicriviroc (BioDeep_00000837658)

   


代谢物信息卡片


(5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide

化学式: C41H52N4O4S (696.3709072)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C
InChI: InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+

描述信息

COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist
D065100 - CCR5 Receptor Antagonists
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

2 个代谢物同义名

Cenicriviroc; (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng. Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. European journal of gastroenterology & hepatology. 2023 01; 35(1):1-14. doi: 10.1097/meg.0000000000002471. [PMID: 36468565]
  • Daniel Clark Files, Frank Tacke, Alexandra O'Sullivan, Patrick Dorr, William G Ferguson, William G Powderly. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS pathogens. 2022 06; 18(6):e1010547. doi: 10.1371/journal.ppat.1010547. [PMID: 35749425]
  • Suzanna L Attia, Samir Softic, Marialena Mouzaki. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clinical and translational science. 2021 01; 14(1):11-19. doi: 10.1111/cts.12839. [PMID: 32583961]
  • Vinicius M Alves, Tesia Bobrowski, Cleber C Melo-Filho, Daniel Korn, Scott Auerbach, Charles Schmitt, Eugene N Muratov, Alexander Tropsha. QSAR Modeling of SARS-CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2. Molecular informatics. 2021 01; 40(1):e2000113. doi: 10.1002/minf.202000113. [PMID: 33405340]
  • Mika Okamoto, Masaaki Toyama, Masanori Baba. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020 10; 182(?):104902. doi: 10.1016/j.antiviral.2020.104902. [PMID: 32739404]
  • F Anthony Romero, Christopher T Jones, Yingzi Xu, Martijn Fenaux, Randall L Halcomb. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. Journal of medicinal chemistry. 2020 05; 63(10):5031-5073. doi: 10.1021/acs.jmedchem.9b01701. [PMID: 31930920]
  • Sujan Dilly Penchala, Jasmini Alagaratnam, Elizabeth Challenger, Alieu Amara, Laura Else, Alan Winston, Saye Khoo. The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. Biomedical chromatography : BMC. 2020 Jan; 34(1):e4711. doi: 10.1002/bmc.4711. [PMID: 31629375]
  • S Bowler, C Siriwardhana, B I Mitchell, M L D'Antoni, D Ogata-Arakaki, S Souza, R Yee, L M A Gangcuangco, D C Chow, L C Ndhlovu, C Shikuma. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. HIV research & clinical practice. 2019 Aug; 20(4-5):123-129. doi: 10.1080/25787489.2020.1719319. [PMID: 32013805]
  • Maria Eugenia Guicciardi, Christy E Trussoni, Anuradha Krishnan, Steven F Bronk, Maria J Lorenzo Pisarello, Steven P O'Hara, Patrick L Splinter, Yandong Gao, Pamela Vig, Alexander Revzin, Nicholas F LaRusso, Gregory J Gores. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. Journal of hepatology. 2018 09; 69(3):676-686. doi: 10.1016/j.jhep.2018.05.018. [PMID: 29802947]
  • Dongke Yu, Shi-Ying Cai, Albert Mennone, Pamela Vig, James L Boyer. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver international : official journal of the International Association for the Study of the Liver. 2018 06; 38(6):1128-1138. doi: 10.1111/liv.13698. [PMID: 29356312]
  • Oliver Krenkel, Tobias Puengel, Olivier Govaere, Ali T Abdallah, Jana C Mossanen, Marlene Kohlhepp, Anke Liepelt, Eric Lefebvre, Tom Luedde, Claus Hellerbrand, Ralf Weiskirchen, Thomas Longerich, Ivan G Costa, Quentin M Anstee, Christian Trautwein, Frank Tacke. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology (Baltimore, Md.). 2018 04; 67(4):1270-1283. doi: 10.1002/hep.29544. [PMID: 28940700]
  • Daniela A Covino, Cristina Purificato, Laura Catapano, Clementina M Galluzzo, Maria Cristina Gauzzi, Stefano Vella, Eric Lefebvre, Star Seyedkazemi, Mauro Andreotti, Laura Fantuzzi. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz. Frontiers in immunology. 2018; 9(?):1839. doi: 10.3389/fimmu.2018.01839. [PMID: 30135687]
  • Debby Reuveni, Yael Gore, Patrick S C Leung, Yael Lichter, Itay Moshkovits, Ayelet Kaminitz, Eli Brazowski, Eric Lefebvre, Pamela Vig, Chen Varol, Zamir Halpern, Oren Shibolet, Merrill Eric Gershwin, Ehud Zigmond. The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis. Frontiers in immunology. 2018; 9(?):1852. doi: 10.3389/fimmu.2018.01852. [PMID: 30158929]
  • Melanie Thompson, Michael Saag, Edwin DeJesus, Joseph Gathe, Jay Lalezari, Alan L Landay, Jerry Cade, Jeffrey Enejosa, Eric Lefebvre, Judith Feinberg. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS (London, England). 2016 Mar; 30(6):869-78. doi: 10.1097/qad.0000000000000988. [PMID: 26636929]
  • Eric Lefebvre, Graeme Moyle, Ran Reshef, Lee P Richman, Melanie Thompson, Feng Hong, Hsin-L Chou, Taishi Hashiguchi, Craig Plato, Dominic Poulin, Toni Richards, Hiroyuki Yoneyama, Helen Jenkins, Grushenka Wolfgang, Scott L Friedman. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PloS one. 2016; 11(6):e0158156. doi: 10.1371/journal.pone.0158156. [PMID: 27347680]
  • Victor G Kramer, Said Hassounah, Susan P Colby-Germinario, Maureen Oliveira, Eric Lefebvre, Thibault Mesplède, Mark A Wainberg. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. The Journal of antimicrobial chemotherapy. 2015 Mar; 70(3):750-6. doi: 10.1093/jac/dku451. [PMID: 25433008]
  • Masanori Baba, Katsunori Takashima, Hiroshi Miyake, Naoyuki Kanzaki, Koichiro Teshima, Xin Wang, Mitsuru Shiraishi, Yuji Iizawa. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrobial agents and chemotherapy. 2005 Nov; 49(11):4584-91. doi: 10.1128/aac.49.11.4584-4591.2005. [PMID: 16251299]
  • W E Criss, F Murad, H Kimura. Properties of guanylate cyclase from rat kidney cortex and transplantable kidney tumors. Journal of cyclic nucleotide research. 1976; 2(1):11-9. doi: NULL. [PMID: 5471]